Overview

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Status:
Completed

Trial end date:
2015-10-31

Target enrollment:

Participant gender:

Summary

This study was a multicenter, randomized, double-blind, placebo, parallel-controlled, dose-finding Phase II clinical trial to find the optimal dose of LY03005 Extended-release Tablets for the treatment of MDD and to evaluate the preliminary efficacy and safety, providing a basis for the design of phase III clinical trials and the determination of dosing regimens.

Phase:

Phase 1

Details

Lead Sponsor:

Luye Pharma Group Ltd.

Collaborator:

Shandong Luye Pharmaceutical Co., Ltd.